货号 (SKU)

包装规格

是否现货

价格

数量

Ab169305-100μg

100μg

现货

Ab169305-1mg

1mg

现货

Ab169305-5mg

5mg

现货

Ab169305-10mg

10mg

期货

基本信息

产品名称	Denosumab (anti-TNFSF11), 肿瘤坏死因子配体超家族成员 11 抑制剂
别名	地诺单抗 \| 迪诺苏单抗 \| 地舒单抗 \| TNFSF11抗体 \| TNFSF11单克隆抗体 \| TNFSF11药靶抗体 \| RANKL抗体 \| RANKL单克隆抗体 \| RANKL药靶抗体 \| CD254抗体 \| CD254单克隆抗体 \| CD254药靶抗体
英文别名	Denosumab \| AMG-162 \| Prolia \| Xgeva \| Immunoglobulin G2 \| Ranmark \| CD254 antibody \| hRANKL2 antibody \| ODF antibody \| OPGL antibody \| OPTB2 antibody \| Osteoclast differentiation factor antibody \| Osteoprotegerin ligand antibody \| Rank Ligand antibody \|
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
生化机理	Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy.
宿主种属	人(Human)
特异性	RANKL
应用	ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
种属反应性	人(Human),食蟹猴(Cynomolgus monkey)
偶联	Unconjugated
作用类型	抑制剂
作用机制	肿瘤坏死因子配体超家族成员 11 抑制剂

产品属性

抗体类型	Primary antibody
克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG1
轻链亚型	kappa
SDS-PAGE	26.6 kDa (Light Chain) & 51.2 kDa (Heavy Chain), under reducing conditions; 178.0 kDa, under non-reducing conditions.
纯化方法	Protein A purified
纯度	>95%
来源	CHO supernatant
物理外观	Liquid
储存缓冲液	Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	长期储存-20℃（24个月）；收货后建议分装，避免反复冻融。
CAS编号和信息	615258-40-7
分子类型	抗体

图片

SEC: Denosumab (anti-TNFSF11) (Ab169305)

Denosumab (anti-TNFSF11) (Ab169305) - SEC
The purity of Denosumab (anti-TNFSF11) (Ab169305) is more than 95% verified by HPLC.

关联靶点（人）

TNFSF11 Tclin 肿瘤坏死因子配体超家族成员 11(Tumor necrosis factor ligand superfamily member 11) (0 活性数据)

点击查看靶蛋白信息： TNFSF11

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

安全和危险性（GHS）

SDS英文版

质量标准

质量标准

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到8个结果

批号(Lot Number)	证书类型	日期	货号
ZJ25F0420821	分析证书	25-04-24	Ab169305
ZJ25F0420820	分析证书	25-04-24	Ab169305
ZJ25F0420819	分析证书	25-04-24	Ab169305
ZJ24F1012827	分析证书	24-10-24	Ab169305
ZJ24F1012826	分析证书	24-10-24	Ab169305
ZJ24F1012825	分析证书	24-10-24	Ab169305
ZJ23F1001443	分析证书	23-10-26	Ab169305
ZJ23F1001442	分析证书	23-10-26	Ab169305

参考文献

1. Coleman RE. (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity.. Clin Cancer Res, 12 (20 Pt 2): (6243s-6249s). [PMID:17062708]
2. Stewart AF. (2005) Clinical practice. Hypercalcemia associated with cancer.. N Engl J Med, 352 (4): (373-9). [PMID:15673803]
3. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH et al.. (2006) Denosumab in postmenopausal women with low bone mineral density.. N Engl J Med, 354 (8): (821-31). [PMID:16495394]
4. Liu C, Chen X, Zhi X, Weng W, Li Q, Li X, Zou Y, Su J, Hu HG.. (2018) Structure-based development of an osteoprotegerin-like glycopeptide that blocks RANKL/RANK interactions and reduces ovariectomy-induced bone loss in mice.. Eur J Med Chem, 145 (661-672). [PMID:29348072] [10.1016/j.ejmech.2018.01.022]
5. Jiang M, Peng L, Yang K, Wang T, Yan X, Jiang T, Xu J, Qi J, Zhou H, Qian N, Zhou Q, Chen B, Xu X, Deng L, Yang C.. (2019) Development of Small-Molecules Targeting Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-Receptor Activator of Nuclear Factor-κB (RANK) Protein-Protein Interaction by Structure-Based Virtual Screening and Hit Optimization.. J Med Chem, 62 (11): (5370-5381). [PMID:31082234] [10.1021/acs.jmedchem.8b02027]
6. Rinotas V,Papakyriakou A,Violitzi F,Papaneophytou C,Ouzouni MD,Alexiou P,Strongilos A,Couladouros E,Kontopidis G,Eliopoulos E,Douni E. (2020) Discovery of Small-Molecule Inhibitors of Receptor Activator of Nuclear Factor-κB Ligand with a Superior Therapeutic Index.. J Med Chem, 63 (20.0): (12043-12059). [PMID:32955874] [10.1021/acs.jmedchem.0c01316]
7. Wong, B R BR and 11 more authors.. (1997) TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells.. The Journal of biological chemistry, (3): [PMID:9312132]
8. Anderson, D M DM and 9 more authors.. (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.. Nature, (13): [PMID:9367155]
9. Lacey, D L DL and 23 more authors.. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.. Cell, (17): [PMID:9568710]
10. Nagai, M M, Kyakumoto, S S and Sato, N N.. (2000) Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation.. Biochemical and biophysical research communications, (16): [PMID:10708588]
11. Body, Jean-Jacques JJ and 14 more authors.. (2003) A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.. Cancer, (1): [PMID:12548591]
12. Melchert, Magda M and List, Alan A.. (2007) The thalidomide saga.. The international journal of biochemistry & cell biology, [PMID:17369076]
13. Sobacchi, Cristina C and 20 more authors.. (2007) Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL.. Nature genetics, [PMID:17632511]
14. Lipton, Allan A and Jun, Susie S.. (2008) RANKL inhibition in the treatment of bone metastases.. Current opinion in supportive and palliative care, [PMID:18685421]
15. Akobeng, Anthony K AK and Stokkers, Pieter C PC.. (2009) Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease.. The Cochrane database of systematic reviews, (15): [PMID:19370685]
16. Reuter, Simone S, Gupta, Subash C SC, Phromnoi, Kanokkarn K and Aggarwal, Bharat B BB.. (2012) Thiocolchicoside suppresses osteoclastogenesis induced by RANKL and cancer cells through inhibition of inflammatory pathways: a new use for an old drug.. British journal of pharmacology, [PMID:21955206]
17. Luan, Xudong X and 8 more authors.. (2012) Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin.. Journal of immunology (Baltimore, Md. : 1950), (1): [PMID:22664871]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

Denosumab (anti-TNFSF11), 肿瘤坏死因子配体超家族成员 11 抑制剂

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

图片

关联靶点（人）

作用机制

安全和危险性（GHS）

质量标准

质检证书（CoA,COO,BSE/TSE 和分析图谱)

参考文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器

Denosumab (anti-TNFSF11), 肿瘤坏死因子配体超家族成员 11 抑制剂

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

图片

关联靶点（人）

作用机制

安全和危险性（GHS）

质量标准

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关产品

参考文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器